$0.09
−9.28%Price chart
Feb 20Feb 25Mar 2Mar 5Mar 10Mar 13Mar 18Mar 23
Key dataMar 23, 2026
Open$0.17
From 52W high−86.97%
Volume18674.00
Market cap$5.11M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataMar 23, 2026
Open
$0.17
From 52W high
−86.97%
Volume
18674.00
Market cap
$5.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
46.1
MomentumView details →
1D Return
−9.28%
YTD Return
−10.32%
SummaryUpdated Sep 1, 2025
Klotho Neurosciences, Inc. (NASDAQ:KLTO) is an early-stage biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases, cancer, and cardiovascular disorders. Originally founded as Anew Medical, Inc., the company rebranded to Klotho Neurosciences in September 2024 to reflect its focus on therapies based on the klotho protein, which plays a crucial role in aging and longevity. Headquartered in Omaha, Nebraska, the company is currently in the preclinical development stage with no approved products or revenue generation.
Similar companies
Latest newsMore news →
Greenland Mines formed a Strategic Advisory Board with three industry leaders to support project strategy, studies, permitting and partnerships.6d agoJason Hawkins was appointed to the Board of Greenland Mines Ltd effective September 8, 2026.9d agoShalom Hirschman and Riad El-Dada resigned from the Board of Directors of Greenland Mines Ltd effective September 8, 2026.9d ago